Monthly ReportFeb 1–28, 2025
Sepsis, February 2025 edition
We read 84 papers and selected 5.
Summary
February 2025 sepsis research showed a strong convergence of mechanistic immunology, rapid diagnostics, predictive analytics, and evidence-based reassessment of clinical policy. Translational studies identified actionable pathways including fucosylated haptoglobin–Mincle signaling, endothelial GSDMD-mediated vascular injury, and S100A8/A9–RAGE–Drp1-driven muscle mitochondrial fragmentation. Diagnostic development accelerated through plasma cell-free DNA metagenomics, droplet digital PCR, and longitudinal deep-learning models for earlier bloodstream infection recognition. At the clinical-practice level, systematic-review and randomized-trial evidence questioned SEP-1 as a mortality-reducing metric and found that initiating aspirin in early sepsis increased major bleeding without improving organ dysfunction.
Selected Articles
1. A bladder-blood immune barrier constituted by suburothelial perivascular macrophages restrains uropathogen dissemination.
This mechanistic study identified suburothelial perivascular macrophages that capture uropathogenic E. coli, preserve inflamed vascular integrity, and use METosis with MMP-13 to sequester bacteria and recruit neutrophils. Monocyte-derived replenishment after infection provided protection against recurrent urinary tract infection, defining a bladder–blood immune barrier that may limit progression from urinary infection to urosepsis.
Impact: The study reveals a previously unrecognized tissue-level defense mechanism against urosepsis and provides a biologically coherent basis for prevention strategies targeting macrophage training, METosis, or MMP-13.
Clinical Implications: Human validation of suburothelial perivascular macrophage signatures could support preventive strategies for recurrent urinary infection and urosepsis. Any intervention modulating extracellular trap formation or MMP-13 will require careful assessment of tissue injury and infection-control effects.
Key Findings
- Suburothelial perivascular macrophages captured uropathogenic E. coli and preserved inflamed vessel integrity.
- METosis and MMP-13-mediated bacterial sequestration promoted neutrophil recruitment across the urothelial barrier.
- Monocyte-derived replenishment after infection protected against recurrent urinary tract infection.
2. Fluoxetine promotes IL-10-dependent metabolic defenses to protect from sepsis-induced lethality.
Preclinical studies showed that fluoxetine increased circulating IL-10 independently of peripheral serotonin, prevented sepsis-associated hypertriglyceridemia and cardiac metabolic dysfunction, and reduced mortality in animal models. IL-10 was necessary for the protective immunometabolic effect.
Impact: The study provides a clearly defined, testable mechanism for repurposing an approved drug as host-directed sepsis therapy and links immune modulation to cardiac and lipid metabolism.
Clinical Implications: The findings justify carefully designed phase 2 trials with IL-10, triglyceride, cardiac function, and safety endpoints. They do not support routine clinical use before human efficacy and safety are established.
Key Findings
- Fluoxetine increased circulating IL-10 independently of peripheral serotonin.
- IL-10 was required to prevent sepsis-associated hypertriglyceridemia and cardiac metabolic dysfunction.
- Fluoxetine reduced sepsis-induced lethality in preclinical models.
3. The Effect of Severe Sepsis and Septic Shock Management Bundle (SEP-1) Compliance and Implementation on Mortality Among Patients With Sepsis: A Systematic Review.
This PROSPERO-registered systematic review of 17 observational studies found inconsistent associations between SEP-1 compliance or implementation and mortality. No study provided moderate- or high-certainty evidence that SEP-1 reduces mortality, and methodological heterogeneity prevented meta-analysis. The findings challenge the use of SEP-1 as a mortality-linked quality metric.
Impact: The review directly addresses a major national sepsis quality metric and highlights the absence of high-quality causal evidence linking SEP-1 compliance to improved survival.
Clinical Implications: Hospitals should avoid allowing process compliance to displace interventions with demonstrated patient benefit. Policymakers may need to redesign sepsis metrics toward risk-adjusted outcomes, timeliness, safety, and patient-centered measures.
Key Findings
- Seventeen observational studies showed mixed associations between SEP-1 compliance or implementation and mortality.
- No included study had low risk of bias or provided moderate- or high-certainty mortality evidence.
- Methodological heterogeneity prevented meta-analysis and supported reconsideration of SEP-1 policy use.
4. Elevated levels of S100A8 and S100A9 exacerbate muscle mitochondrial fragmentation in sepsis-induced muscle atrophy.
This translational study connected sepsis-associated muscle atrophy with an S100A8/A9–RAGE–Drp1 pathway that promotes mitochondrial fission and myocyte atrophy. Clinical muscle-index changes were associated with 60-day mortality, while inhibition of S100A8/A9, RAGE, or Drp1 improved mitochondrial function and reduced atrophy in experimental models.
Impact: The paper links a clinically meaningful post-sepsis complication to a defined and potentially druggable molecular pathway, integrating patient outcomes with mechanistic and intervention data.
Clinical Implications: S100A8/A9 may serve as a biomarker for patients at risk of ICU-acquired weakness. RAGE or Drp1 modulation warrants early-phase translational studies, but efficacy, timing, and effects on host antimicrobial defense require evaluation.
Key Findings
- Change in skeletal muscle index was independently associated with 60-day mortality in septic patients.
- Sepsis increased S100A8/A9 expression and mitochondrial dysfunction in skeletal muscle.
- S100A8/A9 activated RAGE and Drp1-dependent mitochondrial fragmentation, while pathway inhibition reduced atrophy.
5. Utilising routinely collected clinical data through time series deep learning to improve identification of bacterial bloodstream infections: a retrospective cohort study.
In a retrospective cohort of 20,850 patients, an LSTM model using up to 14 days of laboratory trajectories predicted pathogenic bloodstream infection with an AUROC of 0.97 in temporal hold-out testing. CRP, eosinophil, and platelet trajectories were important predictors, and the time-series approach outperformed static models.
Impact: The study demonstrates that routinely collected longitudinal data can support high-performance, individualized bloodstream infection prediction before culture results are available.
Clinical Implications: An externally validated model could help prioritize cultures, rapid molecular testing, antimicrobial escalation, or stewardship-guided de-escalation. Prospective evaluation is essential to determine whether model alerts improve outcomes without increasing unnecessary antibiotic use.
Key Findings
- The LSTM model achieved AUROC 0.97 and AUPRC 0.65 in temporal hold-out testing.
- Longitudinal CRP, eosinophil, and platelet patterns were important predictors.
- The time-series model outperformed static logistic models, particularly for hospital-acquired bloodstream infection.